WallStSmart

Glaukos Corp (GKOS)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 5834% more annual revenue ($36.36B vs $612.84M). MDT leads profitability with a 13.2% profit margin vs -30.7%. GKOS appears more attractively valued with a PEG of 1.64. MDT earns a higher WallStSmart Score of 62/100 (C+).

GKOS

Hold

44

out of 100

Grade: D

Growth: 10.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: 0.57

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GKOSUndervalued (+8.5%)

Margin of Safety

+8.5%

Fair Value

$119.19

Current Price

$180.02

$60.83 discount

UndervaluedFair: $119.19Overvalued
MDTUndervalued (+6.2%)

Margin of Safety

+6.2%

Fair Value

$91.63

Current Price

$87.16

$4.47 discount

UndervaluedFair: $91.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GKOS3 strengths · Avg: 9.7/10
Revenue GrowthGrowth
49.5%10/10

Revenue surging 49.5% year-over-year

EPS GrowthGrowth
1896.0%10/10

Earnings expanding 1896.0% YoY

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$109.30B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

GKOS4 concerns · Avg: 3.3/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
15.5x4/10

Trading at 15.5x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-28.2%2/10

ROE of -28.2% — below average capital efficiency

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : GKOS

The strongest argument for GKOS centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 49.5% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : GKOS

The primary concerns for GKOS are PEG Ratio, Price/Book, Piotroski F-Score.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

GKOS profiles as a hypergrowth stock while MDT is a value play — different risk/reward profiles.

GKOS carries more volatility with a beta of 0.75 — expect wider price swings.

GKOS is growing revenue faster at 49.5% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Glaukos Corp

HEALTHCARE · MEDICAL DEVICES · USA

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?